Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Initiation and completion rates for latent tuberculosis infection treatment: a systematic review

Authors: Andreas Sandgren, Marije Vonk Noordegraaf-Schouten, Femke van Kessel, Anke Stuurman, Anouk Oordt-Speets, Marieke J. van der Werf

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Control of latent tuberculosis infection (LTBI) is an important step towards tuberculosis elimination. Preventive treatment will prevent the development of disease in most cases diagnosed with LTBI. However, low initiation and completion rates affect the effectiveness of preventive treatment. The objective was to systematically review data on initiation rates and completion rates for LTBI treatment regimens in the general population and specific populations with LTBI.

Methods

A systematic review of the literature (PubMed, Embase) published up to February 2014 was performed.

Results

Forty-five studies on initiation rates and 83 studies on completion rates of LTBI treatment were found. These studies provided initiation rates (IR) and completion rates (CR) in people with LTBI among the general population (IR 26–99 %, CR 39–96 %), case contacts (IR 40–95 %, CR 48–82 %), healthcare workers (IR 47–98 %, CR 17–79 %), the homeless (IR 34–90 %, CR 23–71 %), people who inject drugs (IR 52–91 %, CR 38–89 %), HIV-infected individuals (IR 67–92 %, CR 55–95 %), inmates (IR 7–90 %, CR 4–100 %), immigrants (IR 23–97 %, CR 7–86 %), and patients with comorbidities (IR 82–93 %, CR 75–92 %). Generally, completion rates were higher for short than for long LTBI treatment regimens.

Conclusion

Initiation and completion rates for LTBI treatment regimens were frequently suboptimal and varied greatly within and across different populations.
Appendix
Available only for authorised users
Literature
1.
go back to reference European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Stockholm: ECDC; 2015. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Stockholm: ECDC; 2015.
2.
go back to reference Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41:140–56.PubMed Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41:140–56.PubMed
3.
go back to reference Barry 3rd CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845–55.PubMedPubMedCentral Barry 3rd CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845–55.PubMedPubMedCentral
5.
go back to reference Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. 2002;185:401–4.PubMed Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. 2002;185:401–4.PubMed
6.
go back to reference Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677–86.PubMed Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677–86.PubMed
7.
go back to reference National Institute for Health and Care Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE clinical guideline. Manchester: NICE; 2011. p. 67. National Institute for Health and Care Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE clinical guideline. Manchester: NICE; 2011. p. 67.
8.
go back to reference Canadian Tuberculosis Standards, 7th Edition. In: Menzies D, editor. Canadian Tuberculosis Standards. 7th ed. Ottawa: Canadian Thoracic Society, The Canadian Lung Association, Public Health Agency of Canada; 2014. Canadian Tuberculosis Standards, 7th Edition. In: Menzies D, editor. Canadian Tuberculosis Standards. 7th ed. Ottawa: Canadian Thoracic Society, The Canadian Lung Association, Public Health Agency of Canada; 2014.
9.
go back to reference Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–54. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–54.
10.
go back to reference Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419–28.PubMed Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419–28.PubMed
11.
go back to reference Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12:1235–54.PubMed Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12:1235–54.PubMed
12.
go back to reference Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14:551–9.PubMed Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14:551–9.PubMed
13.
go back to reference Anger HA, Proops D, Harris TG, et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis. 2012;54:1287–95.PubMed Anger HA, Proops D, Harris TG, et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis. 2012;54:1287–95.PubMed
14.
go back to reference Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14:e292–7.PubMed Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14:e292–7.PubMed
15.
go back to reference Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166:1863–70.PubMed Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166:1863–70.PubMed
16.
go back to reference Nuzzo JB, Golub JE, Chaulk P, Shah M. Analysis of Latent Tuberculosis Infection Treatment Adherence Among Refugees and Other Patient Groups Referred to the Baltimore City Health Department TB Clinic, February 2009-March 2011. J Immigr Minor Health. 2015;17(1):56–65.PubMed Nuzzo JB, Golub JE, Chaulk P, Shah M. Analysis of Latent Tuberculosis Infection Treatment Adherence Among Refugees and Other Patient Groups Referred to the Baltimore City Health Department TB Clinic, February 2009-March 2011. J Immigr Minor Health. 2015;17(1):56–65.PubMed
17.
go back to reference Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis. 2008;12:160–7.PubMed Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis. 2008;12:160–7.PubMed
18.
go back to reference Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect. 2013;67:424–32.PubMedPubMedCentral Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect. 2013;67:424–32.PubMedPubMedCentral
19.
go back to reference Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest. 2002;122:1609–14.PubMed Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest. 2002;122:1609–14.PubMed
20.
go back to reference World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015. p. 38. World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015. p. 38.
21.
go back to reference Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentral Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentral
22.
go back to reference Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.PubMedPubMedCentral Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.PubMedPubMedCentral
23.
go back to reference Lee SH, Yim JJ, Kim HJ, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect. 2012;140:1028–35.PubMed Lee SH, Yim JJ, Kim HJ, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect. 2012;140:1028–35.PubMed
24.
go back to reference Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL. Latent tuberculosis infection: screening and treatment in an urban setting. J Community Health. 2013;38:941–50.PubMedPubMedCentral Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL. Latent tuberculosis infection: screening and treatment in an urban setting. J Community Health. 2013;38:941–50.PubMedPubMedCentral
25.
go back to reference Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012;12:468.PubMedPubMedCentral Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012;12:468.PubMedPubMedCentral
26.
go back to reference Machado Jr A, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis. 2009;13:719–25.PubMed Machado Jr A, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis. 2009;13:719–25.PubMed
27.
go back to reference Centers for Disease Control and Prevention (CDC). Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection--Chickasaw County, Mississippi, June 1999-March 2002. MMWR Morb Mortal Wkly Rep. 2003;52:222–4. Centers for Disease Control and Prevention (CDC). Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection--Chickasaw County, Mississippi, June 1999-March 2002. MMWR Morb Mortal Wkly Rep. 2003;52:222–4.
28.
go back to reference Rutherford ME, Ruslami R, Anselmo M, et al. Management of children exposed to mycobacterium tuberculosis: a public health evaluation in west java, indonesia. Bull World Health Organ. 2013;91:932–41.PubMedPubMedCentral Rutherford ME, Ruslami R, Anselmo M, et al. Management of children exposed to mycobacterium tuberculosis: a public health evaluation in west java, indonesia. Bull World Health Organ. 2013;91:932–41.PubMedPubMedCentral
29.
go back to reference Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159:295–300.PubMed Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159:295–300.PubMed
30.
go back to reference Lashley M. A targeted testing program for tuberculosis control and prevention among Baltimore city’s homeless population. Public Health Nurs. 2007;24:34–9.PubMed Lashley M. A targeted testing program for tuberculosis control and prevention among Baltimore city’s homeless population. Public Health Nurs. 2007;24:34–9.PubMed
31.
go back to reference Brassard P, Bruneau J, Schwartzman K, Senecal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis. 2004;8:988–93.PubMed Brassard P, Bruneau J, Schwartzman K, Senecal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis. 2004;8:988–93.PubMed
32.
go back to reference Scholten JN, Driver CR, Munsiff SS, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis. 2003;37:1686–92.PubMed Scholten JN, Driver CR, Munsiff SS, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis. 2003;37:1686–92.PubMed
33.
go back to reference Snyder DC, Paz EA, Mohle-Boetani JC, Fallstad R, Black RL, Chin DP. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Am J Respir Crit Care Med. 1999;160:178–85.PubMed Snyder DC, Paz EA, Mohle-Boetani JC, Fallstad R, Black RL, Chin DP. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Am J Respir Crit Care Med. 1999;160:178–85.PubMed
34.
go back to reference Bark CM, Morrison CS, Salata RA, et al. Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda. Int J Tuberc Lung Dis. 2010;14:1647–9.PubMed Bark CM, Morrison CS, Salata RA, et al. Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda. Int J Tuberc Lung Dis. 2010;14:1647–9.PubMed
35.
go back to reference Oni T, Tsekela R, Kwaza B, et al. A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town. PLoS One. 2012;7:e52489.PubMedPubMedCentral Oni T, Tsekela R, Kwaza B, et al. A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town. PLoS One. 2012;7:e52489.PubMedPubMedCentral
36.
go back to reference Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest. 2002;122:1292–8.PubMed Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest. 2002;122:1292–8.PubMed
37.
go back to reference Nolan CM, Roll L, Goldberg SV, Elarth AM. Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med. 1997;155:583–6.PubMed Nolan CM, Roll L, Goldberg SV, Elarth AM. Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med. 1997;155:583–6.PubMed
38.
go back to reference Minodier P, Lamarre V, Carle ME, Blais D, Ovetchkine P, Tapiero B. Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. J Infect Public Health. 2010;3:67–75.PubMed Minodier P, Lamarre V, Carle ME, Blais D, Ovetchkine P, Tapiero B. Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. J Infect Public Health. 2010;3:67–75.PubMed
39.
go back to reference Trauer JM, Krause VL. Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust. 2011;194:579–82.PubMed Trauer JM, Krause VL. Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust. 2011;194:579–82.PubMed
40.
go back to reference Young J, Edick T, Klee D, O’Connor ME. Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. Pediatr Infect Dis J. 2012;31:e147–51.PubMed Young J, Edick T, Klee D, O’Connor ME. Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. Pediatr Infect Dis J. 2012;31:e147–51.PubMed
41.
go back to reference Bastos ML, Menzies D, Belo MT, et al. Changes in QuantiFERON(R)-TB Gold In-Tube results during treatment for tuberculous infection. Int J Tuberc Lung Dis. 2013;17:909–16.PubMed Bastos ML, Menzies D, Belo MT, et al. Changes in QuantiFERON(R)-TB Gold In-Tube results during treatment for tuberculous infection. Int J Tuberc Lung Dis. 2013;17:909–16.PubMed
42.
go back to reference Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640–7.PubMed Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640–7.PubMed
43.
go back to reference Jimenez-Fuentes MA, de Souza-Galvao ML, Mila Auge C, Solsona Peiro J, Altet-Gomez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013;17:326–32.PubMed Jimenez-Fuentes MA, de Souza-Galvao ML, Mila Auge C, Solsona Peiro J, Altet-Gomez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013;17:326–32.PubMed
44.
go back to reference Matteelli A, Olliaro P, Signorini L, et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis. 1999;3:1043–6.PubMed Matteelli A, Olliaro P, Signorini L, et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis. 1999;3:1043–6.PubMed
45.
go back to reference Matteelli A, Casalini C, Raviglione MC, et al. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med. 2000;162:1653–5.PubMed Matteelli A, Casalini C, Raviglione MC, et al. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med. 2000;162:1653–5.PubMed
46.
go back to reference Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445–9.PubMed Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445–9.PubMed
47.
go back to reference Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689–97.PubMed Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689–97.PubMed
48.
go back to reference Rivero A, Lopez-Cortes L, Castillo R, et al. Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients. Enferm Infecc Microbiol Clin. 2007;25:305–10.PubMed Rivero A, Lopez-Cortes L, Castillo R, et al. Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients. Enferm Infecc Microbiol Clin. 2007;25:305–10.PubMed
49.
go back to reference Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173:922–6.PubMedPubMedCentral Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173:922–6.PubMedPubMedCentral
50.
go back to reference Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715–22.PubMed Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715–22.PubMed
51.
go back to reference Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.PubMed Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.PubMed
52.
go back to reference Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005;9:276–81.PubMed Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005;9:276–81.PubMed
53.
go back to reference Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest. 2001;119:833–7.PubMed Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest. 2001;119:833–7.PubMed
54.
go back to reference Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631–6.PubMedPubMedCentral Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631–6.PubMedPubMedCentral
55.
go back to reference Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis. 2005;9:270–5.PubMed Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis. 2005;9:270–5.PubMed
56.
go back to reference Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK. Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. J Urban Health. 1999;76:461–7.PubMedPubMedCentral Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK. Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. J Urban Health. 1999;76:461–7.PubMedPubMedCentral
57.
go back to reference Morisky DE, Ebin VJ, Malotte CK, Coly A, Kominski G. Assessment of tuberculosis treatment completion in an ethnically diverse population using two data sources. Implications for treatment interventions. Eval Health Prof. 2003;26:43–58.PubMed Morisky DE, Ebin VJ, Malotte CK, Coly A, Kominski G. Assessment of tuberculosis treatment completion in an ethnically diverse population using two data sources. Implications for treatment interventions. Eval Health Prof. 2003;26:43–58.PubMed
58.
go back to reference Sadaphal P, Astemborski J, Graham NM, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33:1687–91.PubMedPubMedCentral Sadaphal P, Astemborski J, Graham NM, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33:1687–91.PubMedPubMedCentral
59.
go back to reference Sarivalasis A, Bodenmann P, Langenskiold E, Lutchmaya-Flick C, Daher O, Zellweger JP. High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton. Swiss Med Wkly. 2013;143:w13860.PubMed Sarivalasis A, Bodenmann P, Langenskiold E, Lutchmaya-Flick C, Daher O, Zellweger JP. High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton. Swiss Med Wkly. 2013;143:w13860.PubMed
60.
go back to reference Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003;167:824–7.PubMed Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003;167:824–7.PubMed
61.
go back to reference Valls V, Ena J. Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy. Clin Rheumatol. 2014;34:29.PubMed Valls V, Ena J. Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy. Clin Rheumatol. 2014;34:29.PubMed
62.
go back to reference White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002;162:1044–50.PubMed White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002;162:1044–50.PubMed
63.
go back to reference White MC, Tulsky JP, Menendez E, Goldenson J, Kawamura LM. Incidence of TB in inmates with latent TB infection: 5-year follow-up. Am J Prev Med. 2005;29:295–301.PubMed White MC, Tulsky JP, Menendez E, Goldenson J, Kawamura LM. Incidence of TB in inmates with latent TB infection: 5-year follow-up. Am J Prev Med. 2005;29:295–301.PubMed
64.
go back to reference LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443–7.PubMed LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443–7.PubMed
65.
go back to reference Clerk N, Sisson K, Antunes G. Latent tuberculosis: concordance and duration of treatment regimens. Br J Nurs. 2011;20:824–7.PubMed Clerk N, Sisson K, Antunes G. Latent tuberculosis: concordance and duration of treatment regimens. Br J Nurs. 2011;20:824–7.PubMed
66.
go back to reference Duarte R, Carvalho A, Correia A. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection. Public Health. 2012;126:760–2.PubMed Duarte R, Carvalho A, Correia A. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection. Public Health. 2012;126:760–2.PubMed
67.
go back to reference Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183:E173–9.PubMedPubMedCentral Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183:E173–9.PubMedPubMedCentral
68.
go back to reference Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med. 2006;3:e494.PubMedPubMedCentral Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med. 2006;3:e494.PubMedPubMedCentral
69.
go back to reference O’Grady J, Maeurer M, Atun R, et al. Tuberculosis in prisons: anatomy of global neglect. Eur Respir J. 2011;38:752–4.PubMed O’Grady J, Maeurer M, Atun R, et al. Tuberculosis in prisons: anatomy of global neglect. Eur Respir J. 2011;38:752–4.PubMed
70.
go back to reference Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med. 2000;162:460–4.PubMed Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med. 2000;162:460–4.PubMed
71.
go back to reference Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–50.PubMed Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–50.PubMed
72.
go back to reference Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–55.PubMed Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–55.PubMed
73.
go back to reference Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592–5.PubMed Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592–5.PubMed
75.
go back to reference Centers for Disease Control and Prevention (CDC). Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996–1997. MMWR Morb Mortal Wkly Rep. 2000;49:685–7. Centers for Disease Control and Prevention (CDC). Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996–1997. MMWR Morb Mortal Wkly Rep. 2000;49:685–7.
76.
go back to reference Al-Darraji HA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis. 2012;16:871–9.PubMed Al-Darraji HA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis. 2012;16:871–9.PubMed
77.
go back to reference Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735–9. Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735–9.
78.
go back to reference Horsburgh Jr CR, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137:401–9.PubMed Horsburgh Jr CR, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137:401–9.PubMed
79.
go back to reference Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130:1712–7.PubMed Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130:1712–7.PubMed
80.
go back to reference Lopez G, Wood M, Ayesta FJ. 10 years of innovation in the treatment of latent tuberculosis infection: a comparison between standard and short course therapies in directly observed therapy. Rev Esp Sanid Penit. 2011;13:3–14.PubMed Lopez G, Wood M, Ayesta FJ. 10 years of innovation in the treatment of latent tuberculosis infection: a comparison between standard and short course therapies in directly observed therapy. Rev Esp Sanid Penit. 2011;13:3–14.PubMed
81.
go back to reference Fresard I, Bridevaux PO, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly. 2011;141:w13240.PubMed Fresard I, Bridevaux PO, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly. 2011;141:w13240.PubMed
82.
go back to reference Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J. 2007;30:728–35.PubMed Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J. 2007;30:728–35.PubMed
83.
go back to reference Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis. 2009;49:424–7.PubMed Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis. 2009;49:424–7.PubMed
84.
go back to reference Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49:1883–9.PubMed Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49:1883–9.PubMed
85.
go back to reference Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;7:CD007545. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;7:CD007545.
86.
go back to reference Eurostat Press Office. Immigration in the EU27 in 2006 In: newsrelease E, ed. 2008. Eurostat Press Office. Immigration in the EU27 in 2006 In: newsrelease E, ed. 2008.
87.
go back to reference Comparing Migrant Stock: The Foreign Born in Australia, Canada, and the United States by Region of Origin. 2014. Accessed 15 Dec 2014. Comparing Migrant Stock: The Foreign Born in Australia, Canada, and the United States by Region of Origin. 2014. Accessed 15 Dec 2014.
88.
go back to reference Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist. 2010;3:63–72.PubMedPubMedCentral Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist. 2010;3:63–72.PubMedPubMedCentral
89.
go back to reference Cruz AT, Starke JR. Increasing adherence for latent tuberculosis infection therapy with health department-administered therapy. Pediatr Infect Dis J. 2012;31:193–5.PubMed Cruz AT, Starke JR. Increasing adherence for latent tuberculosis infection therapy with health department-administered therapy. Pediatr Infect Dis J. 2012;31:193–5.PubMed
90.
go back to reference Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged > or =35 years. Clin Infect Dis. 2000;31:826–9.PubMed Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged > or =35 years. Clin Infect Dis. 2000;31:826–9.PubMed
91.
go back to reference Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest. 2008;133:862–8.PubMed Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest. 2008;133:862–8.PubMed
92.
go back to reference Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh Jr CR. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007;54:262–6.PubMed Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh Jr CR. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007;54:262–6.PubMed
93.
go back to reference Cain KP, Garman KN, Laserson KF, et al. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med. 2012;186:273–9.PubMed Cain KP, Garman KN, Laserson KF, et al. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med. 2012;186:273–9.PubMed
94.
go back to reference Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J. Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis. 2004;39:667–72.PubMed Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J. Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis. 2004;39:667–72.PubMed
95.
go back to reference Shah M, DiPietro D, Greenbaum A, et al. Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PLoS One. 2012;7:e36551.PubMedPubMedCentral Shah M, DiPietro D, Greenbaum A, et al. Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PLoS One. 2012;7:e36551.PubMedPubMedCentral
96.
go back to reference Langenskiold E, Herrmann FR, Luong BL, Rochat T, Janssens JP. Contact tracing for tuberculosis and treatment for latent infection in a low incidence country. Swiss Med Wkly. 2008;138:78–84.PubMed Langenskiold E, Herrmann FR, Luong BL, Rochat T, Janssens JP. Contact tracing for tuberculosis and treatment for latent infection in a low incidence country. Swiss Med Wkly. 2008;138:78–84.PubMed
97.
go back to reference Chee CB, Teleman MD, Boudville IC, Do SE, Wang YT. Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore. Int J Tuberc Lung Dis. 2004;8:226–31.PubMed Chee CB, Teleman MD, Boudville IC, Do SE, Wang YT. Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore. Int J Tuberc Lung Dis. 2004;8:226–31.PubMed
98.
go back to reference Grinsdale JA, Ho CS, Banouvong H, Kawamura LM. Programmatic impact of using QuantiFERON(R)-TB Gold in routine contact investigation activities. Int J Tuberc Lung Dis. 2011;15:1614–20.PubMed Grinsdale JA, Ho CS, Banouvong H, Kawamura LM. Programmatic impact of using QuantiFERON(R)-TB Gold in routine contact investigation activities. Int J Tuberc Lung Dis. 2011;15:1614–20.PubMed
99.
go back to reference Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033–8.PubMed Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033–8.PubMed
100.
go back to reference Balkhy HH, Miller TL, Ali S, et al. Compliance with postexposure screening and treatment of latent tuberculosis infection among healthcare workers in a tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol. 2014;35:176–81.PubMed Balkhy HH, Miller TL, Ali S, et al. Compliance with postexposure screening and treatment of latent tuberculosis infection among healthcare workers in a tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol. 2014;35:176–81.PubMed
101.
go back to reference Tavitian SM, Spalek VH, Bailey RP. A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers. Am J Health Syst Pharm. 2003;60:1856–61.PubMed Tavitian SM, Spalek VH, Bailey RP. A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers. Am J Health Syst Pharm. 2003;60:1856–61.PubMed
102.
go back to reference Xu Y, Schwartzman K. Referrals for positive tuberculin tests in new health care workers and students: a retrospective cohort study. BMC Public Health. 2010;10:28.PubMedPubMedCentral Xu Y, Schwartzman K. Referrals for positive tuberculin tests in new health care workers and students: a retrospective cohort study. BMC Public Health. 2010;10:28.PubMedPubMedCentral
103.
go back to reference Golub JE, Astemborski J, Ahmed M, et al. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr. 2008;49:532–7.PubMedPubMedCentral Golub JE, Astemborski J, Ahmed M, et al. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr. 2008;49:532–7.PubMedPubMedCentral
104.
go back to reference Mugisha B, Bock N, Mermin J, et al. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis. 2006;10:761–7.PubMed Mugisha B, Bock N, Mermin J, et al. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis. 2006;10:761–7.PubMed
105.
go back to reference Lincoln T, Brannan GL, Lynch V, et al. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. Int J Tuberc Lung Dis. 2004;8:306–11.PubMed Lincoln T, Brannan GL, Lynch V, et al. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. Int J Tuberc Lung Dis. 2004;8:306–11.PubMed
106.
go back to reference Ailinger RL, Black P, Nguyen N, Lasus H. Predictors of Adherence to Latent Tuberculosis Infection Therapy in Latino Immigrants. J Community Health Nurs. 2007;24:191–8.PubMedPubMedCentral Ailinger RL, Black P, Nguyen N, Lasus H. Predictors of Adherence to Latent Tuberculosis Infection Therapy in Latino Immigrants. J Community Health Nurs. 2007;24:191–8.PubMedPubMedCentral
107.
go back to reference Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics. 2006;117:e148–56.PubMed Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics. 2006;117:e148–56.PubMed
108.
go back to reference Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci. 2007;22:779–83.PubMedPubMedCentral Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci. 2007;22:779–83.PubMedPubMedCentral
109.
go back to reference Stucchi RS, Boin IF, Angerami RN, Zanaga L, Ataide EC, Udo EY. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Transplant Proc. 2012;44:2406–10.PubMed Stucchi RS, Boin IF, Angerami RN, Zanaga L, Ataide EC, Udo EY. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Transplant Proc. 2012;44:2406–10.PubMed
110.
go back to reference Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6:995–1000.PubMed Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6:995–1000.PubMed
111.
go back to reference McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis. 2005;41:1125–33.PubMed McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis. 2005;41:1125–33.PubMed
112.
go back to reference Chang SH, Eitzman SR, Nahid P, Finelli ML. Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents. J Infect Public Health. 2014;7:145–52.PubMed Chang SH, Eitzman SR, Nahid P, Finelli ML. Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents. J Infect Public Health. 2014;7:145–52.PubMed
113.
go back to reference Codecasa LR, Murgia N, Ferrarese M, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013;17:903–8.PubMed Codecasa LR, Murgia N, Ferrarese M, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013;17:903–8.PubMed
114.
go back to reference Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis. 2013;17:169–74.PubMed Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis. 2013;17:169–74.PubMed
115.
go back to reference Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis. 2010;14:1104–11.PubMedPubMedCentral Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis. 2010;14:1104–11.PubMedPubMedCentral
116.
go back to reference Kan B, Kalin M, Bruchfeld J. Completing treatment for latent tuberculosis: patient background matters. Int J Tuberc Lung Dis. 2013;17:597–602.PubMed Kan B, Kalin M, Bruchfeld J. Completing treatment for latent tuberculosis: patient background matters. Int J Tuberc Lung Dis. 2013;17:597–602.PubMed
117.
go back to reference Vinnard C, Gopal A, Linkin DR, Maslow J. Isoniazid toxicity among an older veteran population: a retrospective cohort study. Tuberc Res Treat. 2013;2013:549473.PubMedPubMedCentral Vinnard C, Gopal A, Linkin DR, Maslow J. Isoniazid toxicity among an older veteran population: a retrospective cohort study. Tuberc Res Treat. 2013;2013:549473.PubMedPubMedCentral
118.
go back to reference White MC, Gournis E, Kawamura M, Menendez E, Tulsky JP. Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. Int J Tuberc Lung Dis. 2003;7:30–5.PubMed White MC, Gournis E, Kawamura M, Menendez E, Tulsky JP. Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. Int J Tuberc Lung Dis. 2003;7:30–5.PubMed
119.
go back to reference Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 2010;14:701–7.PubMed Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 2010;14:701–7.PubMed
120.
go back to reference Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest. 2005;127:1296–303.PubMed Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest. 2005;127:1296–303.PubMed
121.
go back to reference Bandyopadhyay T, Murray H, Metersky ML. Cost-effectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest. 2002;121:1771–5.PubMed Bandyopadhyay T, Murray H, Metersky ML. Cost-effectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest. 2002;121:1771–5.PubMed
122.
go back to reference Priest DH, Vossel Jr LF, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis. 2004;39:1764–71.PubMed Priest DH, Vossel Jr LF, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis. 2004;39:1764–71.PubMed
123.
go back to reference Ailinger RL, Dear MR. Adherence to tuberculosis preventive therapy among Latino immigrants. Public Health Nurs. 1998;15:19–24.PubMed Ailinger RL, Dear MR. Adherence to tuberculosis preventive therapy among Latino immigrants. Public Health Nurs. 1998;15:19–24.PubMed
124.
go back to reference Ailinger RL, Moore JB, Nguyen N, Lasus H. Adherence to latent tuberculosis infection therapy among latino immigrants. Public Health Nurs. 2006;23:307–13.PubMed Ailinger RL, Moore JB, Nguyen N, Lasus H. Adherence to latent tuberculosis infection therapy among latino immigrants. Public Health Nurs. 2006;23:307–13.PubMed
125.
go back to reference Sanchez-Garcia EM, Gamallo R, Blanco-Moure A, Viejo MA, Amador L, Anibarro L. Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies. Infection. 2013;41:903–7.PubMed Sanchez-Garcia EM, Gamallo R, Blanco-Moure A, Viejo MA, Amador L, Anibarro L. Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies. Infection. 2013;41:903–7.PubMed
Metadata
Title
Initiation and completion rates for latent tuberculosis infection treatment: a systematic review
Authors
Andreas Sandgren
Marije Vonk Noordegraaf-Schouten
Femke van Kessel
Anke Stuurman
Anouk Oordt-Speets
Marieke J. van der Werf
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1550-y

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue